Jon has been reporting on stock markets for over twenty-five years for audio text companies (remember them?!), newswires, and websites. He helped set up MarketEye News for ICV/Topic in the 1990’s before moving on to become a Markets reporter at AFX News. After over 10 years, which saw him rise to the dizzy heights of Markets Editor at AFX, the firm’s acquisition by Thomson Corp and subsequent takeover of Reuters, he moved on in 2012. Prior to Proactive Investors, he was News Editor for thisismoney.co.uk, the Mail Online’s financial website.
The FTSE 100 listed company said its total revenue would reach US$17bn-18bn a year by 2020, a downgrade of its previous estimate of achieving US$20bn in revenue by that date
Celgene is paying US$1.1bn in cash upfront for the San Diego-based company, plus an additional US$1.4bn depending on the receipt of US Food and Drug Administration milestone approvals
The Nasdaq listed firm, which develops treatments for liver disorders in children, said it will continue to operate its business under the jurisdiction of the bankruptcy court
The biopharma company said it will make an initial upfront payment to Cell Design of about US$175mln and additional payments of up to US$322mln upon meeting certain milestones
Jefferies has cut its rating for the FTSE 250-listed firm to ‘underperform’ from ‘hold and chopped its target price to 895p from 1,074p after lowering its earnings per share forecasts
ImmuPharma’s chairman, Tim McCarthy, said: "Importantly we continue to see robust safety and we look forward with continued confidence to reporting top line results of the study in Q1 2018"
The US banking giant raised its stock price target for Valeant to US$12 from US10 a share, but that was still well below Wednesday’s closing price of US$22.05
The AIM-listed UK healthcare firm said 31 potential distributors attended the meeting, covering 14 important cities and provinces, including Beijing and Shanghai